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Autoimmune mechanisms causing diverse psychiatric symptoms are increasingly 
recognized and brought about a paradigm shift in neuropsychiatry. Identification of 
underlying antibodies against neuronal ion channels or receptors led to the speculation 
that a number of patients go misdiagnosed with a primary psychiatric disease. 
However, there is no clear consensus which clinical signs in psychiatric patients should 
prompt further investigations including measurement of anti-neuronal autoantibodies. 
We therefore aimed to analyze the presenting symptoms in patients with autoimmune 
encephalitis and the time between symptom onset and initiation of antibody diagnostics. 
For this, we recruited 100 patients from the Charité Center for Autoimmune Encephalitis 
between May and October 2016, including all types of autoimmune encephalitides. 
Psychiatric abnormalities were the most common clinical symptoms and were the 
presenting sign in 60%. One-third of patients were initially hospitalized in a psychiatric 
ward. All patients positive for antibodies against the N-methyl-d-aspartate receptor 
showed behavioral changes, hallucinations, memory deficits, catatonia, or delusions. 
Patients positive for antibodies against other cell surface or intracellular antigens were 
often hospitalized with a psychosomatic diagnosis. The time between occurrence 
of first symptoms and antibody testing was often alarmingly prolonged. In patients 
with symptom onset between 2013 and 2016, the mean delay was 74  days, in 
cases diagnosed between 2007 and 2012 even 483  days, suggesting though that 
increased awareness of this novel disease group helped to expedite proper diagnosis 
and treatment. By analyzing the medical records in detail, we identified clinical signs 
that may help to assist in earlier diagnosis, including seizures, catatonia, autonomic 
instability, or hyperkinesia. Indeed, reanalyzing the whole cohort using these “red flags” 
led to a 58% reduction of time between symptom onset and diagnosis. We conclude 
that the timely diagnosis of an autoimmune psychiatric disease can be facilitated by 
use of the described clinical warning signs, likely enabling earlier immunotherapy and 
better prognosis. Also, the threshold for cerebrospinal fluid analysis and autoantibody 
testing should be low.
Keywords: autoimmune encephalitis, schizophreniform syndrome, cerebrospinal fluid analysis, anti-neuronal 
autoantibodies, immunotherapy
Table 1 | classification of encephalitis groups in the present study and commonly associated clinical features.
encephalitis 
groups of the 
present study
antibodies number of 
patients
Psychiatric symptoms additional symptoms Typical patient
(A) NMDAR 
encephalitis 
(n = 53)
NMDA receptor n = 53 (53%) Psychosis, schizophreniform 
illness, catatonia, 
hallucinations, aggression
Epileptic seizures, dyskinesia, 
autonomic instability, speech 
dysfunction, decreased consciousness
Young women, association with 
ovarian teratomas
(B) Non-NMDAR 
cell surface 
antigens  
(n = 24)
Caspr2 n = 4 (4%) Insomnia, panic attacks, 
schizophreniform illness, 
depression
Morvan syndrome, neuromyotonia, 
muscle spasms, fasciculations
Middle age or elderly patients, may 
be associated with thymoma
LGI1 n = 14 (14%) Amnesia, confusion, 
memory deficits,  
depression
Limbic encephalitis, faciobrachial 
dystonic seizures, hyponatremia
Middle age or elderly patients, 
male:female (2:1), may be 
associated with thymoma
Metabotropic 
glutamate 
receptor 5
n = 2 (2%) Behavioral changes, 
emotional instability,  
memory deficits
Limbic encephalitis,  
Ophelia syndrome
Young adults, may be associated 
with Hodgkin’s lymphoma
Glycine receptor n = 1 (1%) Behavioral changes, 
schizophreniform syndrome
Stiff-person syndrome (SPS) or 
progressive encephalomyelitis with 
rigidity and myoclonus, hyperekplexia
middle age or elderly patients, may 
be associated with thymomas and 
lymphomas
(C) Antibodies 
against 
intracellular 
antigens  
(n = 23)
Synaptic antigens: 
anti-GAD 
antibodies
n = 9 (9%) Schizophreniform illness, 
autism, attention-deficit/
hyperactivity disorder
Limbic encephalitis, seizures, SPS, 
brainstem dysfunction, ataxia
Middle age or elderly patients, 
might be associated with small-cell 
lung cancer
Onconeuronal 
antigens: anti-Yo, 
-Hu, -CV2, -Ri, 
-Ma2 antibodies
n = 14 (14%) Behavioral changes Limbic encephalitis, cerebellar 
degeneration, sensory neuropathy
Elderly patients, often with 
malignant tumors (small-cell 
lung carcinoma, Hu; testicular 
seminoma, Ma2)
NMDAR, N-methyl-d-aspartate-receptor; LGI1, leucine-rich glioma inactivated 1; Caspr2, contactin associated protein 2.
2
Herken and Prüss Red Flags in Autoimmune Psychosis
Frontiers in Psychiatry | www.frontiersin.org February 2017 | Volume 8 | Article 25
inTrODUcTiOn
The growing number of newly described autoimmune encepha-
litides has drawn a remarkable link between immunology and 
psychiatry within the last several years (1–3). Since the pioneer-
ing discovery of N-methyl-d-aspartate receptor (NMDAR) 
autoantibodies (4), various further antibodies against receptors 
and ion channels were identified in patients with psychiatric 
abnormalities, such as against AMPA, GABA, glycine receptors, 
metabotropic glutamate receptor 5 (mGluR5), and dopamine-
D2 receptors (Table  1), not only in humans (5). Patients are 
often first hospitalized in psychiatric departments before being 
transferred to a neurology ward (6, 7), stimulating the intriguing 
question of whether a subset of patients may go misdiagnosed 
with a primary psychiatric disease (1, 2, 8, 9). Recently, a high 
prevalence of cerebrospinal fluid (CSF) abnormalities including 
the detection of anti-neuronal autoantibodies has been observed 
in 54.4% of psychotic patients (10), highlighting their potential 
role in psychiatry and underlining the need for increased clini-
cal and scientific awareness in order to not overlook treatable 
etiologies.
Antibody-mediated encephalitides can be categorized 
based on the presence of anti-neuronal antibodies targeting 
(i) neuronal cell surface antigens and (ii) intracellular antigens 
(11, 12). Autoantibodies directed to cell surface proteins are 
more frequently found in patients with psychiatric abnor-
malities, likely due to a suspected direct pathogenic effect 
(12–14). The demonstration of specific effects of NMDAR 
antibody-containing CSF in  vivo convincingly substantiates 
the link between autoantibodies and the schizophreniform 
syndrome seen in these patients (15). Most recent work using 
CSF-derived human monoclonal NMDAR antibodies showed 
that the antibody is sufficient to change NMDAR expression 
and electrophysiology (16). Thus, the presence of this antibody 
alone represents a risk factor for neuropsychiatric symptoms, 
supporting the need for sufficiently aggressive immunotherapy 
in affected patients.
Such a clear causative role of autoantibodies on psychiatric 
symptoms has yet to be shown for further surface-directed 
antibodies. Nonetheless, psychotic symptoms are common in 
numerous other autoimmune encephalitides (Table  1). For 
example, patients with antibodies against the voltage-gated 
potassium channel complex (VGKCc) often present with 
hallucinations, depression, and memory deficits (13, 14, 17). 
Neuropsychiatric symptoms were found in 44% of VGKCc 
antibody-positive patients, occasionally treated for primary 
psychiatric diagnoses (14). Less well known, patients with 
antibodies against intracellular targets can also present with 
psychiatric symptoms (18).
The prognosis of autoimmune encephalitides largely depends 
on the rapid initiation of immunotherapy. Any delay in diagnosis 
causes costs and morbidity, while early immunotherapy results 
in substantial recovery in 70–80% of the patients (6, 19–23). This 
is especially striking considering the often severe course of the 
disease, sometimes requiring prolonged episodes of intensive 
care unit treatment and mechanical ventilation (6). Delayed 
FigUre 1 | classification of encephalitis groups analyzed in the present study. Underlying autoantibodies show different patterns of brain binding using 
immunofluorescence testing. (a) Patients with NMDAR encephalitis and high-level autoantibodies against the NR1 subunit of the NMDAR. (b) Patients with 
non-NMDAR antibodies targeting neuronal surfaces, such as antibodies against the metabotropic glutamate receptor 5 (mGluR5). (c) Patients with antibodies 
targeting intracellular epitopes, such as anti-Hu antibodies.
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recognition of the disease can also result in inadequate use of 
neuroleptics, which in patients with NMDAR encephalitis fre-
quently worsens the symptoms, leading to the working diagnosis 
of a neuroleptic malignant syndrome (7).
We therefore aimed to retrospectively ascertain the time and 
frequency of delayed diagnosis of autoimmune encephalitides 
and asked whether specific clinical signs can assist in earlier 
recognition, antibody testing, and proper diagnosis of the disease. 
Indeed, a number of warning signs (“red flags”) can help to facili-
tate the timely diagnosis of an autoimmune psychiatric disease, 
likely enabling earlier immunotherapy and better prognosis.
MaTerials anD MeThODs
Patient selection
N = 100 patients with different forms of autoimmune encepha-
litides were recruited in the Charité Centre for Autoimmune 
Encephalitis from May to October 2016. Patients were grouped 
in three categories (Table 1):
(A) Anti-NMDAR encephalitis (n = 53), defined by a compatible 
clinical picture and positive IgG-NMDAR antibodies in the 
CSF (Figure 1A).
(B) Non-NMDAR surface antibodies (n  =  24), including 
patients with antibodies against the neuronal cell surface 
antigens LGI1 (n = 14), CASPR2 (n = 4), mGluR5 (n = 2, 
Figure 1B), glycine receptor (n = 1) and against an unknown 
epitope determined on brain section immunofluorescence 
testing (n = 3).
(C) Antibodies against intracellular epitopes (n =  23), includ-
ing patients with GAD antibodies (n = 9) or onconeuronal 
antibodies, such as Yo, Hu, Ri, or CV2 (n = 14, Figure 1C).
informed consent
Written informed consent was received from participants at the 
Charité Department of Neurology or their representatives prior 
to inclusion in the study, and analyses were approved by the 
Charité University Hospital Institutional Review Board.
clinical Data collection
Most patients were hospitalized in the Charité Department of 
Neurology during the disease course. Medical charts were ret-
rospectively analyzed, and clinical and para-clinical information 
was collected during follow-up visits in the outpatient clinic or 
via email/telephone interviews. The following information was 
systematically retrieved from medical records: age, sex, date of 
disease onset, neurological and psychiatric symptoms during 
initial clinical presentation, psychiatric and neurological signs 
during follow-up, department of initial hospitalization, details of 
psychiatric hospitalization, symptoms that led to determination 
of antibodies, date of diagnosis, and time from first symptoms to 
diagnosis.
resUlTs
Demographic Data
Median age in our cohort was 41 years (range 14–92 years) and 
71% were female. Patients positive for NMDAR antibodies were 
younger (mean age 30 [14–57] years) and mainly women (91%). 
In contrast, patients with antibodies against non-NMDAR sur-
face antigens were predominantly of male gender (67%) and older 
(mean age 53 [29–78] years). Patients positive for antibodies 
against intracellular proteins were predominantly female (65%), 
mean age was 56 (37–92) years.
initial hospitalization in a Psychiatric 
Department
In order to estimate the overlapping symptoms with primary 
psychiatric disorders, we analyzed the frequency of patients ini-
tially hospitalized in a psychiatric department and the frequency 
of psychotic symptoms at first evaluation and during follow-up. 
N = 31 patients (31%) were initially hospitalized on a Psychiatry 
ward, commonly for psychotic or suspected psychosomatic 
symptoms. Almost two-thirds of all patients (n  =  60; 60%) 
showed psychotic symptoms at the beginning of the disease, 
even if hospitalization was not required, 7% presented with 
psychosomatic symptoms.
Table 2 | Presenting clinical symptoms in all 100 patients.
initial signs and symptoms all patients (100) nMDar (53) non-nMDar (24) intracellular antigens (23)
Psychiatric
Acute behavioral changes 56 (56%) 46 (87%) 7 (29%) 3 (13%)
Hallucinations (visual, auditory) 25 (25%) 23 (43%) 1 (4%)
Memory deficits (retro- and anterograde amnesia) 22 (22%) 11 (21%) 8 (33%) 4 (17%)
Confusion/aggression 18 (18%) 11 (21%) 6 (25%) 1 (4%)
Paranoid delusions 17 (17%) 13 (26%) 2 (8%) 1 (4%)
Depressed mood 13 (13%) 10 (19%) 4 (16%) 1 (4%)
Catatonia 10 (10%) 10 (19%)
Mutism 8 (8%) 8 (15%)
Anorexia 1 (1%) 1 (2%)
Any of the above symptoms 65 (65%) 53 (100%) 14 (58%) 7 (30%)
neurological
Sensorimotor deficits 30 (30%) 8 (15%) 7 (29%) 13 (57%)
Seizures 10 (19%) 2 (8%) 5 
Generalized tonic-clonic 13 (13%) 9 (17%) 1 (4%) 3 (13%)
Focal 4 (4%) 1 (2%) 1 (4%) 2 (9%)
Faciobrachial dystonic seizures 7 (7%) 7 (29%)
Speech dysfunction (pressured speech, verbal reduction) 15 (15%) 10 (19%) 4 (16%)
Movement disorders 11 (11%) 7 (13%) 1 (4%) 3 (13%)
Headache 12 (12%) 9 (17%) 1 (4%) 2 (9%)
Reduced levels of consciousness 7 (7%) 5 (9%) 2 (8%)
Paralysis 7 (7%) 4 (8%) 1 (4%) 2 (9%)
Cerebellar ataxia 10 (10%) 1 (2%) 3 (12%) 7 (30%)
Diplopia 7 (7%) 3 (6%) 4 (17%)
Any of the above symptoms 67 (67%) 39 (74%) 20 (83%) 20 (87%)
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Psychiatric symptoms were not equally distributed across the 
three encephalitis groups. All patients with NMDAR antibodies 
(n =  53) showed psychotic symptoms. In patients positive for 
antibodies against other neuronal surface or intracellular anti-
gens, psychosomatic symptoms were common at presentation: 
8/24 in the non-NMDAR group (33%), 5/23 in the intracellular 
antigens group (22%). However, psychotic symptoms did also 
occur: 6/24 in the non-NMDAR group (25%), 4/23 in the intra-
cellular group (17%). Of the NMDAR antibody-positive patients, 
21/53 (40%) were seen by a psychiatrist at first evaluation, while 
this was the case for only one patient positive for intracellular 
protein antibodies (4%).
initial symptoms
The frequency of first clinical signs was again not equally distrib-
uted between the encephalitis groups (Table 2). Patients positive 
for NMDAR antibodies typically presented with psychiatric 
symptoms and either developed a spectrum of neurological 
abnormalities, such as seizures, movement, or speech disor-
ders, or already showed them at first evaluation. Their initial 
psychiatric symptoms were acute behavioral changes (n =  46; 
87%), hallucinations (n = 23; 43%), paranoid delusions (n = 13; 
26%), and memory deficits, especially short-term memory loss 
(n = 11; 21%). Also, mutism (n = 8; 15%), catatonia (n = 10; 
19%), and depressive symptoms (n = 10; 19%) were commonly 
seen at presentation. One young woman got initially hospital-
ized with the clinical picture of anorexia. First symptoms in 
some patient were neurological, consisting of epileptic seizures 
(n = 10; 19%), speech dysfunction such as pressured speech and 
verbal reduction (n =  10; 19%), dyskinesia (n =  7; 13%), and 
headache (n = 9; 17%).
Patients of the non-NMDAR group presented also with psy-
chiatric symptoms in most cases, such as acute behavioral changes 
(n =  7; 29%), aggression/confusion (n =  6; 25%), or memory 
deficits (n = 8; 33%). Hallucinations and paranoid delusions were 
also seen (Table  2). The neurological symptoms of this group 
were more characteristic and included faciobrachial dystonic 
seizures (FBDS, in patients with LGI1 antibodies) (n = 7; 29%) 
and sensorimotor deficits (n = 7; 29%).
Patients positive for intracellular epitope antibodies pre-
sented less frequently with psychiatric symptoms, including 
acute behavioral changes and memory deficits. The majority of 
symptoms in this group were neurological, such as sensorimotor 
deficits (n = 13; 57%), cerebellar ataxia (n = 7; 30%), movement 
disorders (n =  3; 13%), and generalized tonic-clonic seizures 
(n = 3; 13%).
In most patients of all three groups, both psychiatric and 
neurological symptoms occurred during the first month of dis-
ease. Interestingly, n = 13 (13%) of all patients presented with a 
depressed mood, in four cases leading to the diagnosis of major 
depression. Appearance of additional neurological symptoms led 
to reclassification of diagnosis.
Which clinical Features led to 
examination of autoantibodies?
We next determined which clinical symptoms, routine laboratory 
findings, or imaging abnormalities triggered the testing for autoan-
tibodies in all 100 patients, the results of which finally allowed 
the firm diagnosis of autoimmune encephalitis (Table 3). Indeed, 
several clinical constellations of neurological and psychiatric 
symptoms were more common than others to stimulate antibody 
testing. We semi-quantitatively classified these constellations as 
Table 3 | clinical symptoms and constellations that led to the determination of anti-neuronal antibodies in all 100 patients.
symptoms all patients (100) nMDar (53) non-nMDar (24) intracellular antigens (23)
Epileptic seizures 14 (14%) 10 (19%) 2 (8%) 2 (8%)
Cerebrospinal fluid (CSF) abnormalitiesa and absent  
evidence for infectious encephalitis
13 (13%) 12 (27%) 1 (4%)
Abnormal postures or movements 4 (4%) 4 (7%)
Reduced levels of consciousness 4 (4%) 4 (7%)
Aphasia or dysarthria 3 (3%) 3 (6%)
Lack of improvement with antipsychotics 5 (5%) 4 (7%) 1 (4%)
Autonomic instability 2 (2%) 2 (4%)
Suspicious MRI or EEG findings 10 (10%) 3 (6%) 5 (20%) 2 (8%)
Steroid-responsive autoimmune thyroiditis 3 (3%) 2 (4%) 1 (4%)
Lack of improvement with antiepileptic medication 2 (2%) 1 (2%) 1 (4%)
Focal neurological deficits 3 (3%) 1 (2%) 1 (4%) 1 (4%)
Sensory deficits 3 (3%) 1 (2%) 2 (8%)
Rapidly progressing psychosis 4 (4%) 1 (2%) 2 (8%) 1 (4%)
Suggested by patients or families 3 (3%) 3 (6%)
Positive effect of ex juvantibus immunotherapy 2 (2%) 1 (4%) 1 (4%)
Faciobrachial dystonic seizures 3 (3%) 3 (12%)
Neuromyotonia 1 (1%) 1 (4%)
Cerebellar ataxia 8 (8%) 2 (8%) 6 (26%)
Hyponatremia 2 (2%) 2 (8%)
Paresthesia or malignant tumorb 7 (7%) 7 (30%)
aIncreased white blood cell count or CSF-specific oligoclonal bands.
bSmall-cell lung cancer, testicular seminoma.
Table 4 | Warning signs pointing to an autoimmune etiology in new-
onset psychosis.
Yellow flags •	 Decreased levels of consciousness
•	 Abnormal postures or movements 
(orofacial, limb dyskinesia)
•	 Autonomic instability
•	 Focal neurological deficits
•	 Aphasia or dysarthria
•	 Rapid progression of psychosis (despite 
therapy)
•	 Hyponatremia
•	 Catatonia
•	 Headache
•	 Other autoimmune diseases  
(e.g., thyroiditis)
red flags •	 Cerebrospinal fluid (CSF) lymphocytic 
pleocytosis or CSF-specific oligoclonal 
bands without evidence for infection
•	 Epileptic seizures
•	 Faciobrachial dystonic seizures
•	 Suspected malignant neuroleptic 
syndrome
•	 MRI abnormalities (mesiotemporal 
hyperintensities, atrophy pattern)
•	 EEG abnormalities (slowing, epileptic 
activity or extreme delta brush)
“Red flag” criteria should always prompt determination of anti-neuronal autoantibodies 
in psychiatric patients. “Yellow flag” criteria should raise suspicion of an autoimmune 
etiology and include autoimmune encephalitis in the differential diagnoses, in either 
case if several findings are present.
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“yellow flags” and “red flags,” depending on their power to predict 
the presence of autoantibodies in such patients (Table 4).
In the NMDAR encephalitis group, viral encephalitis was a 
common working diagnosis, often suggested by the clinical pic-
ture, acute neurological changes, and CSF pleocytosis. NMDAR 
autoantibody testing was often initiated once the search for a viral 
or bacterial pathogen remained negative (n = 12; 27%). In all three 
groups, the occurrence of epileptic seizures frequently initiated 
CSF investigation including determination of antibodies (n = 14; 
14%). Suspicious MRI and EEG were another reason for antibody 
testing, in particular in patients with non-NMDAR surface anti-
bodies (n = 5; 20%), but much less in NMDAR antibody-positive 
patients (n = 3; 6%). Patients were frequently transferred from 
a psychiatric to a neurological ward at this point. Similarly, in 
patients hospitalized for a schizophreniform syndrome, detection 
of abnormal neurological signs resulted in antibody testing. These 
deficits included decreased levels of consciousness (n = 4; 7%), 
abnormal postures or movements (n =  4; 7%), and aphasia or 
dysarthria (n = 3; 6%) in patients of the NMDAR encephalitis 
group. Focal neurological signs were the trigger for antibody 
testing in one patient each of the NMDAR (2%), non-NMDAR 
surface antibody (4%), and intracellular epitope antibody (4%) 
groups (Table 3).
Non-NMDAR antibodies testing was performed in several 
cases because of the occurrence of FBDS (n = 3; 12%), sensory 
deficits (n =  2; 8%), or the detection of hyponatremia in the 
context of unexplained neuropsychiatric symptoms (n = 2; 8%). 
In two patients with non-NMDAR surface antibodies, antibody 
testing was initiated because of a rapidly progressing psychosis 
(n =  2; 8%). A common reason to test for antibodies against 
intracellular epitopes was the occurrence of paresthesia in the 
context of a malignant tumor (n =  7; 30%) or clinical deficits 
resulting from cerebellar symptoms (n = 6; 26%).
We further identified seven cases in which the lack of clinical 
improvement after antipsychotic (n =  5; 5%) or antiepileptic 
therapy (n =  2; 2%) led to the suspicion of an autoimmune 
encephalitis. Another two patients with psychotic symptoms 
FigUre 2 | Time between onset of clinical symptoms and diagnosis 
of antibody-associated encephalitis. Comparing patients with disease 
onset between 2007 and 2012 (a) versus 2013 to 2016 (b), the delay from 
symptom onset to the diagnosis of autoimmune encephalitis (light colors) has 
been reduced within the last years, likely due to increased awareness (please 
note the different y-axes). Applying the “red flag” criteria to the same patients 
by reanalyzing medical records resulted in a marked hypothetical reduction of 
the delay until antibody testing and encephalitis diagnosis (dark colors).
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and cognitive impairment had the working diagnosis of 
steroid-responsive encephalopathy with autoimmune thyroidi-
tis (SREAT), which triggered antibody testing that resulted in 
positive NMDAR (n =  2; 4%) and onconeuronal (n =  1; 4%) 
antibodies (Table 3). Finally, in one case, the patient’s family sug-
gested the diagnosis of autoimmune encephalitis after internet 
research, prompting the testing of NMDAR antibodies which 
returned positive.
Taken together, several clinical symptoms and abnormalities 
repeatedly led to antibody testing, bringing about the correct 
diagnosis of autoimmune encephalitis. We consider these warn-
ing signs as “red flags” (Table  4) which might facilitate earlier 
diagnosis of autoimmunity in psychiatric symptoms.
Time from First symptom to Diagnosis
Given that the prognosis in patients with autoimmune encepha-
litis depends on the rapid initiation of immunotherapy, we next 
analyzed the time between symptom onset and diagnosis. For 
this, patients who were treated primarily in a psychiatry depart-
ment (n =  35) were divided in two groups. In the first group, 
symptoms started between 2007 and 2012. Here, the delay was 
very prolonged with a mean time of 483  days (Figure  2A). In 
the second group with symptom onset between 2013 and 2016, 
the mean time between disease onset and diagnosis was 74 days 
(Figure 2B). The reduction was obvious in both groups for which 
data were available, namely the NMDAR encephalitis (reduction 
from 475 to 40 days) and non-NMDAR antibody group (reduc-
tion from 509 to 150 days). It seems likely that increased aware-
ness of this new disease group after 2012 and a lower threshold 
for antibody testing in clinical routine helped to markedly reduce 
the delay, even though there is an obvious need and opportunity 
for further improvement.
earlier Diagnosis of autoimmune 
encephalitis in Psychiatric Patients 
Using the “red Flags”
Having established warning signs (“yellow flags” and “red flags”) 
that may guide clinicians in the indication for autoantibody 
testing in patients with different autoimmune encephalitides 
(Table 4), we then retrospectively applied these criteria to our 
cohort of encephalitis patients hospitalized in a psychiatric 
ward. In this way, we aimed to estimate the potential reduction 
in delay between symptom onset and diagnosis of autoimmune 
encephalitis. Indeed, reanalysis of the medical records showed 
that most patients had well-documented evidence of “yellow 
flag” and “red flag” criteria in their medical records, long before 
an autoimmune etiology and antibody testing was considered. As 
a typical example, a patient with a schizophreniform syndrome 
developed catatonia and autonomic instability (both are “yellow 
flags”) 4  weeks after the symptom onset, but only an epileptic 
seizure 10  weeks after symptom onset prompted autoantibody 
testing and revealed positive NMDAR antibodies. We then 
calculated the time from symptom onset to diagnosis, hypo-
thetically assuming that the first documentation of a “red flag” 
in the medical chart would have resulted in the determination of 
autoantibodies. In this example, using the “yellow flag” and “red 
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flag” criteria reduced the delay from symptom onset to diagnosis 
from 10 to 4 weeks.
Indeed, the analysis of our cohort showed a marked reduc-
tion in the time until diagnosis (Figure 2). For the more recent 
patients with symptom onset between 2013 and 2016, a reduction 
of 58% from 74 to 31 days was detectable. In detail, time between 
appearance of first symptoms and final diagnosis was reduced 
from 40 to 10 days (75%) in patients with NMDAR encephalitis, 
150 to 52  days (65%) in patients with non-NMDAR surface 
antibodies, and 209 to 50 days (76%) in patients with antibodies 
against intracellular epitopes (Figure 2B).
DiscUssiOn
In accordance with recent publications (7, 8, 24), our results con-
firm that a broad spectrum of psychiatric symptoms frequently 
are the first complaints in patients with autoimmune encephalitis. 
While psychosis typically led to hospitalization of patients with 
NMDAR encephalitis, a psychosomatic disorder was often sus-
pected in patients with surface non-NMDAR and intracellular 
epitope antibodies. The “psychosomatic” symptoms included, 
for example, FBDS in LGI1 antibody-positive patients, muscle 
spasms, and fasciculations in Caspr2 antibody-positive patients 
or sensory deficits in patients with onconeuronal antibodies. 
Interestingly, most patients in all three encephalitis groups 
showed additional neurological symptoms during the first month 
of disease.
Analysis of the present cohort of 100 encephalitis patients 
showed that several clinical symptoms or laboratory findings 
eventually led to the suspicion of an autoimmune etiology 
and the determination of autoantibodies. These “yellow flags” 
and “red flags” are summarized in Table 4, classified based on 
their predictive value to point to an underlying autoimmune 
encephalitis in the clinical workup of patients with psychiatric 
abnormalities. Given that systematic controlled trials and 
systematic reviews of cohort or case-control studies are lack-
ing due to the novelty of this field and the relative rarity of 
autoimmune encephalitides, this case series analysis can only 
represent level 4 of evidence. Generally, some constellations are 
very typical for a given form of encephalitis, e.g., the presence 
of new-onset psychosis in young women with ovarian teratomas 
indicating NMDAR encephalitis or the combination of amnesia, 
hyponatremia, and the pathognomonic FBDS (brief repetitive 
stereotyped movements predominantly affecting the arm and 
ipsilateral face) indicating LGI1 antibody encephalitis. Clearly, 
typical features can be absent and delay the proper diagnosis (11, 
25–27). Also, future work will likely add further or modify the 
proposed criteria.
The most common triggers for autoantibody diagnostic 
were CSF abnormalities in the absence of an infectious disease. 
The symptom overlap with viral encephalitis is remarkable 
regarding neurological and psychiatric changes (28, 29), sug-
gesting that autoantibodies should always be determined, at 
the latest if virus diagnostic (using PCR) remains negative. CSF 
is abnormal in almost all patients with NMDAR encephalitis 
during the disease course (11, 24), underlining the relevance 
of routine CSF testing in psychiatric patients. This is also valid 
for the other forms of encephalitis, although patients with LGI1 
antibodies have a lower frequency of CSF pleocytosis (41%) or 
elevated protein (47%) and rarely have intrathecal LGI1 anti-
body synthesis (25).
The occurrence of epileptic seizures in a psychotic patient 
was another common reason to reassess the working diagnosis 
of a primary psychiatric disease and test for antibodies. EEG 
changes not explained by medication are almost always present 
in autoimmune encephalitis. The alterations are rarely specific, 
showing focal or diffuse slow activity frequently associated 
with one or several foci of epileptic activity, eventually reveal-
ing subclinical seizures (27). However, the pattern referred 
to as “extreme delta brush” in NMDAR encephalitis is quite 
disease-specific (30). Suspicious MRI findings led to the cor-
rect diagnosis in relatively few cases in the present cohort 
(10%), which is likely explained by the fact that brain MRIs 
are unremarkable in more than 50% of patients with NMDAR 
encephalitis (11, 23, 28). If present, however, MRI abnormali-
ties should always prompt autoantibody investigation, even 
though other diseases might cause similar imaging changes, 
such as gliomas (25, 28, 31).
Lejuste et al. observed a very high rate of patients with NMDAR 
encephalitis in which intolerance to antipsychotic drugs led to 
transfer to a Neurology department or intensive care unit (7). In 
line with their findings, the combination of autonomic instabil-
ity and increased creatine kinase levels after neuroleptic therapy 
in several cases led to the suspicion of a malignant neuroleptic 
syndrome. Therefore, we included progression under antipsy-
chotic therapy, suspected malignant neuroleptic syndrome and 
autonomic instability to the “red flag” criteria (Table 4). Finally, 
the presence of an autoimmune thyroiditis together with psy-
chotic symptoms and cognitive impairment resulted in antibody 
investigation in three cases in the present cohort. It was shown 
recently that serum thyroid antibodies were elevated in 24.7% 
of 180 psychotic patients (10). Beneficial effects from steroids 
suggest the less well-defined constellation of SREAT (32). 
However, occurrence of specific brain-directed antibodies in our 
cohort (e.g., NMDAR antibodies) support the idea that SREAT 
represents increased susceptibility to autoimmunity, rather than 
that antithyroid antibodies are directly pathogenic. Findings 
of elevated thyroid peroxidase and thyroglobulin antibodies in 
psychotic patients should nonetheless raise suspicion and guide 
autoantibody testing.
Apart from the clinical application of the here proposed 
criteria, the present study reinforces the recent discussion that 
autoantibodies may participate in the development of psychi-
atric disorders, such as schizophrenia, in greater extend than 
previously assumed. For example, the reduction of NMDAR-
specific currents and consecutively impaired glutamatergic 
neurotransmission is well known under the NMDAR hypofunc-
tionality hypothesis of schizophrenia (33). In parallel, synaptic 
and extrasynaptic reduction of NMDAR by autoantibodies in 
NMDAR encephalitis leads to the typical schizophreniform 
symptoms seen in these patients (34). While internalization of 
NMDAR after contact with autoantibodies has been established 
as an important disease mechanism (16, 35), further patholo-
gies are likely to happen in parallel, such as chemokine transfer 
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from immune cells to NMDAR-bearing neurons via volume 
transmission (36). It seems that these novel synaptic and extra-
synaptic autoimmune disorders have brought about a paradigm 
shift in neuropsychiatry, and further research is urgently needed 
to clarify the detailed mechanisms of how autoimmunity and 
inflammation cause or modify neuropsychiatric diseases.
An important finding of our study was the alarmingly 
long delay between first symptoms and the final diagnosis of 
autoimmune encephalitis in many cases. It is known from the 
literature that patients with autoimmune encephalitis have often 
been misdiagnosed with a sole psychiatric disease despite the 
presence of neurological comorbidities (7). We could show here 
that the identification of encephalitis patients occurred much 
faster in more recent cases (2013–2016) compared to earlier 
patients, likely due to increased awareness of this novel disease 
group. The data collectively suggest that continuing increase in 
disease awareness will lead to further shortening of the time 
until diagnosis. This is needed as early and sufficiently aggres-
sive immunotherapy is required for a better prognosis (22, 23, 
25, 26). Using the here proposed “yellow flag” and “red flag” 
criteria will likely facilitate the timely diagnosis of an autoim-
mune psychiatric disease, as demonstrated by the hypothetical 
reanalysis of our cohort for the presence of such clinical signs. 
Finally, we conclude that CSF analysis should become clinical 
routine in patients with new-onset psychosis for several rea-
sons. First, CSF abnormalities were the major indicator for an 
autoimmune encephalitis in psychotic patients. Second, some 
antibodies including NMDAR antibodies can be present in CSF 
only and would therefore be overlooked in serum (37). Third, 
recent data suggest that the rate of CSF abnormalities can be 
>50%, thus being much higher than previously thought and an 
important step to identify patients with treatable etiologies (10). 
Taken together, the threshold for CSF analysis and autoantibody 
testing should be low, in particular, when “red flags” are present.
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